Luoxin Pharmaceuticals Group Stock Co., Ltd.

SZSE:002793 Stok Raporu

Piyasa değeri: CN¥4.7b

Luoxin Pharmaceuticals Group Stock Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Luoxin Pharmaceuticals Group Stock's earnings have been declining at an average annual rate of -61.3%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 26.3% per year.

Anahtar bilgiler

-61.3%

Kazanç büyüme oranı

-64.1%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi10.9%
Gelir büyüme oranı-26.3%
Özkaynak getirisi-37.1%
Net Marj-28.8%
Son Kazanç Güncellemesi30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Luoxin Pharmaceuticals Group Stock Co., Ltd. (SZSE:002793) Held Back By Insufficient Growth Even After Shares Climb 41%

Oct 21
Luoxin Pharmaceuticals Group Stock Co., Ltd. (SZSE:002793) Held Back By Insufficient Growth Even After Shares Climb 41%

Why Investors Shouldn't Be Surprised By Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) Low P/S

Aug 23
Why Investors Shouldn't Be Surprised By Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) Low P/S

Luoxin Pharmaceuticals Group Stock (SZSE:002793) Is Making Moderate Use Of Debt

Jun 25
Luoxin Pharmaceuticals Group Stock (SZSE:002793) Is Making Moderate Use Of Debt

Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) Price Is Right But Growth Is Lacking After Shares Rocket 25%

May 21
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Subdued Growth No Barrier To Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) Price

Feb 28
Subdued Growth No Barrier To Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) Price

Gelir ve Gider Dağılımı

Luoxin Pharmaceuticals Group Stock nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

SZSE:002793 Gelir, gider ve kazançlar (CNY Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 242,418-6971,42370
30 Jun 242,368-6231,30580
31 Mar 242,390-6081,32889
31 Dec 232,364-6611,393112
30 Sep 231,644-9571,316124
30 Jun 231,700-1,2341,317143
31 Mar 232,073-1,3971,481187
01 Jan 233,588-1,2252,249205
30 Sep 225,155-5282,391267
30 Jun 226,177-92,587299
31 Mar 226,9123302,698313
01 Jan 226,4784062,331321
30 Sep 216,8304142,590324
30 Jun 216,8604032,746326
31 Mar 216,5643662,693329
31 Dec 206,0963212,403361
30 Sep 206,3205772,525360
30 Jun 206,3385552,624382
31 Mar 207,0626203,218405
31 Dec 197,5896343,611420
30 Sep 198,5026294,349524
30 Jun 199,6807525,221621
31 Mar 197,7826114,111522
31 Dec 186,2115123,297420
31 Mar 174,3873453,0150
31 Dec 164,1183792,7740
30 Sep 163,8884162,4610
30 Jun 163,7874682,2600
31 Mar 163,7675022,0950
31 Dec 153,6114932,0130
30 Sep 153,3564741,7970
30 Jun 153,0574461,6630
31 Mar 152,9004301,6300
31 Dec 142,7674441,4700
30 Sep 142,7574021,4420
30 Jun 142,7244111,3290
31 Mar 142,5544201,2040
31 Dec 132,5294291,2030

Kaliteli Kazançlar: 002793 is currently unprofitable.

Büyüyen Kar Marjı: 002793 is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 002793 is unprofitable, and losses have increased over the past 5 years at a rate of 61.3% per year.

Büyüme Hızlandırma: Unable to compare 002793's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: 002793 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.2%).


Özkaynak Getirisi

Yüksek ROE: 002793 has a negative Return on Equity (-37.14%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin